<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318812</url>
  </required_header>
  <id_info>
    <org_study_id>2005840-01H</org_study_id>
    <nct_id>NCT00318812</nct_id>
  </id_info>
  <brief_title>Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure</brief_title>
  <official_title>Heme Iron Polypeptide for the Treatment of Iron Deficiency Anemia in Pre-Dialysis Patients: A Pilot Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if oral Heme Iron Polypeptide is as effective as
      intravenous (IV) iron sucrose in the treatment of iron-deficiency anemia for patients with
      chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron deficiency anemia is common in patients with pre-dialysis chronic kidney disease, and is
      associated with significant morbidity. Conventional treatment with oral iron salts or IV iron
      formulations are costly and are associated with side effects. Heme iron polypeptide is a
      newly available formulation of oral iron which can be administered orally, is well absorbed
      by uremic patients, and has potentially fewer side effects.

      Comparison: Iron deficient anemic patients will be randomized to either oral heme iron
      polypeptide or IV iron sucrose for six months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin Concentration at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of Ferritin at 6 months between the 2 Groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin Saturation</measure>
    <time_frame>6 Months</time_frame>
    <description>Comparison of Transferrin Saturation between the Groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Anemia</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Heme Iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venofer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venofer q month IV x 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heme Iron Polypeptide (Proferrin)</intervention_name>
    <description>Heme iron polypeptide 11mg po tid for 6 months</description>
    <arm_group_label>Heme Iron</arm_group_label>
    <other_name>Proferrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose (Venofer)</intervention_name>
    <description>Iron sucrose infusion IV q month x 6 months</description>
    <arm_group_label>Venofer</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eGFR &amp;lt; 30 mL/min

          -  Hb 90-110 g/L

          -  Age &amp;gt; 18

          -  Not on renal replacement therapy

          -  Transferrin saturation &amp;lt; 20% OR Ferritin &amp;lt;100 mcg/L

          -  B12 &amp; folate within reference range

        Exclusion Criteria:

          1. Iron overload (Tsat &gt; 50% or ferritin &gt; 800 μg/L);

          2. malignancy; recurrent gastro-intestinal bleeding, major surgery or infection within
             the last 3 months;

          3. parenteral iron therapy, blood transfusion within the last 3 months;

          4. pregnancy;

          5. contraindication to any study medication and;

          6. inability or refusal to give consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Zimmerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <results_first_submitted>June 26, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2014</results_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized controlled trial (RCT)</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>ferric oxide, saccharated</keyword>
  <keyword>Peptides</keyword>
  <keyword>Heme</keyword>
  <keyword>Iron</keyword>
  <keyword>Erythropoietin,</keyword>
  <keyword>Recombinant</keyword>
  <keyword>Ferritin</keyword>
  <keyword>Transferrin</keyword>
  <keyword>Treatment Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>May 2007 - February 2011, 55 Chronic Kidney Disease patients &gt;18years,with an estimated Glomerular Filtration Rate (eGFR) &lt;30mls/minute and Hemoglobin (Hgb) of 90-110 were recruited. Recruitment was expanded to eGFR ≤60 and Hgb of 90-120g/L (females)and 90-135 g/L (males) with serum ferritin &lt; 100 mcg /L or Transferrin Saturation (TSAT) &lt; 20%)</recruitment_details>
      <pre_assignment_details>15 of the 55 patients were screen failures due to; Hgb too high/low, ferritin level too high, Vitamin B level too low,one had bypass surgery</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Heme Iron</title>
          <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Iron Sucrose</title>
          <description>Iron Sucrose q month IV x 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heme Iron</title>
          <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Iron Sucrose</title>
          <description>Iron Sucrose q month IV x 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" lower_limit="66" upper_limit="83"/>
                    <measurement group_id="B2" value="66" lower_limit="58" upper_limit="76"/>
                    <measurement group_id="B3" value="68" lower_limit="63" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin Concentration at 6 Months</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heme Iron</title>
            <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose</title>
            <description>Iron Sucrose q month IV x 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Concentration at 6 Months</title>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="110" upper_limit="129"/>
                    <measurement group_id="O2" value="113" lower_limit="108" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ferritin</title>
        <description>Comparison of Ferritin at 6 months between the 2 Groups</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heme Iron</title>
            <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose</title>
            <description>Iron Sucrose q month IV x 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Ferritin</title>
          <description>Comparison of Ferritin at 6 months between the 2 Groups</description>
          <units>ug/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="44" upper_limit="104"/>
                    <measurement group_id="O2" value="244" lower_limit="72" upper_limit="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transferrin Saturation</title>
        <description>Comparison of Transferrin Saturation between the Groups</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heme Iron</title>
            <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose</title>
            <description>Iron Sucrose q month IV x 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Transferrin Saturation</title>
          <description>Comparison of Transferrin Saturation between the Groups</description>
          <units>percentage of bound iron sites</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="17" upper_limit="29"/>
                    <measurement group_id="O2" value="21.5" lower_limit="17" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Heme Iron</title>
          <description>Heme Iron Polypeptide 11mg PO tid for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Iron Sucrose</title>
          <description>Iron Sucrose q month IV x 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>Hip iron</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="IV surcrose">Symptomatic Hypotension</sub_title>
                <description>symptomatic hypotesnion was seen in 3 patients in the IV sucrose arm and 0 patients in the HIP arm</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <description>Gastrointestinal complaints were the most common adverse effects in both groups with constipation and abdominal cramps being the most common in HIP group and constipation in IV sucrose group</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title vocab="Hip">abdominal cramps</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment for the trial was a challenge; over 1100 patients screened - 55 consented - 40 randomized</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Deborah Zimmerman, principal investigator</name_or_title>
      <organization>Ottawa Hospital Research Institute</organization>
      <phone>613-738-8400 ext 82534</phone>
      <email>dzimmerman@toh.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

